Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Ignore the noise in GLP-1 stocks. Find the best value instead.
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics (NASDAQ: VKTX) and Roche Holdings (OTC: RHHBY), up 11.3% and 4%, respectively, through 10:05 a.m. ET today, are behind it.
And Novo Nordisk (NYSE: NVO) stock, down 4.9%, is the victim.
Let's start with the background. Currently there are four branded and patent-protected GLP-1 weight-loss drugs on the market. Novo Nordisk owns two of them: Ozempic and Wegovy. Eli Lilly (NYSE: LLY) owns the other two: Mounjaro and Zepbound.
